Hims & Hers Health (HIMS) Stock Forecast & Price Target

$22.61 +0.82 (+3.76%)

(As of 03:05 PM ET)

Hims & Hers Health - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 16 Analyst Ratings

Sell
1

Hold
8

Buy
7

Based on 16 Wall Street analysts who have issued ratings for Hims & Hers Health in the last 12 months, the stock has a consensus rating of "Hold." Out of the 16 analysts, 1 has given a sell rating, 8 have given a hold rating, and 7 have given a buy rating for HIMS.

Consensus Price Target

$20.71
-8.38% Downside

According to the 16 analysts' twelve-month price targets for Hims & Hers Health, the average price target is $20.71. The highest price target for HIMS is $28.00, while the lowest price target for HIMS is $10.00. The average price target represents a forecasted downside of -8.38% from the current price of $22.61.

Get the Latest News and Ratings for HIMS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Hims & Hers Health and its competitors.

HIMS Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	6 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	3 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$20.71	$20.21	$20.29	$12.36
Forecasted Upside	-8.38% Downside	-14.31% Downside	21.33% Upside	52.83% Upside
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Moderate Buy

[625,000% Gain] – Are You Ready for the Next Altcoin Boom? (Ad)

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

HIMS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HIMS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Hims & Hers Health Stock vs. The Competition

Type	Hims & Hers Health	Medical Companies	S&P 500
Consensus Rating Score	2.38	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	-4.98% Downside	26,931.53% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent HIMS News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/20/2024	TD Cowen 4 of 5 stars		Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00	+25.39%
11/14/2024	Bank of America 4 of 5 stars		Downgrade	Buy ➝ Underperform	$32.00 ➝ $18.00	-17.09%
11/6/2024	Deutsche Bank Aktiengesellschaft 3 of 5 stars		Boost Target	Hold ➝ Hold	$23.00 ➝ $27.00	+12.17%
11/5/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$18.00 ➝ $21.00	-3.14%
11/5/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$24.00 ➝ $28.00	+34.87%
8/22/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Macdonald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$24.00	+44.93%
Get the Latest News and Ratings for HIMS and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Hims & Hers Health and its competitors with MarketBeat's FREE daily newsletter.
8/9/2024	Imperial Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Piccolo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ In-Line
7/18/2024	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$13.00 ➝ $23.00	+2.68%
6/27/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$14.00 ➝ $23.00	+19.98%
5/22/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral	$16.00 ➝ $20.00	+13.96%
4/26/2024	Seaport Res Ptn Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Kessler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy
2/27/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$15.00 ➝ $17.00	+22.83%
2/26/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Cherny Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
2/26/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$10.00	+5.04%
1/5/2024	Tigress Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$14.00 ➝ $15.00	+81.38%
8/8/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$14.00	+77.22%
4/11/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$10.00	+2.04%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 03:20 PM ET.

HIMS Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Hims & Hers Health is $20.71, with a high forecast of $28.00 and a low forecast of $10.00.
: 16 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hims & Hers Health in the last twelve months. There is currently 1 sell rating, 8 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HIMS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HIMS, but not buy additional shares or sell existing shares.
: According to analysts, Hims & Hers Health's stock has a predicted downside of -8.38% based on their 12-month stock forecasts.
: Over the previous 90 days, Hims & Hers Health's stock had 1 downgrade by analysts.
: Hims & Hers Health has been rated by research analysts at Bank of America, Canaccord Genuity Group, Deutsche Bank Aktiengesellschaft, Piper Sandler, and TD Cowen in the past 90 days.
: Analysts like Hims & Hers Health less than other "medical" companies. The consensus rating for Hims & Hers Health is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HIMS compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

When it comes to NVDA… “acceleration cycles” are the key (Ad)

Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.

Use this link to see Nvidia Unchained right away!

This page (NYSE:HIMS) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Hims & Hers Health (HIMS) Stock Forecast & Price Target